<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740870</url>
  </required_header>
  <id_info>
    <org_study_id>G050186</org_study_id>
    <nct_id>NCT00740870</nct_id>
  </id_info>
  <brief_title>Melody Transcatheter Pulmonary Valve (TPV) Study: Post Approval Study of the Original Investigational Device Exemption (IDE) Cohort</brief_title>
  <official_title>Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to confirm the long-term functionality of implantation of the
      Medtronic Melody TPV at 5 years is no worse than the historical control established through
      literature review. The secondary objectives are to assess safety, procedural success, and
      clinical utility of transcatheter implantation of the Melody TPV.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Freedom From TPV Dysfunction</measure>
    <time_frame>5 years</time_frame>
    <description>To assess whether long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. This study is designed to test the null hypothesis that the true freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is less than or equal to 36% (PControl). To reject the null hypothesis means that freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is greater than 36% (PControl). The null (H0) and alternative (HA) hypotheses are written as follows:H0: PMelody â‰¤ PControl and HA: PMelody &gt; PControl. TPV dysfunction is a composite outcome defined as the following:
Hemodynamic dysfunction of the TPV
Moderate or greater pulmonary regurgitation, and/or
Mean Right Ventricular Outflow Tract (RVOT) gradient greater than 40 mmHg
RVOT reoperation for conduit dysfunction or device-related reasons
Catheter re-intervention on the TPV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Within 24 Hours post implant</time_frame>
    <description>Procedural success is a composite outcome defined as:
Melody TPV fixated within the desired location
Right Ventricle (RV) - Pulmonary Artery (PA) peak-to-peak gradient (measured in the catheterization lab) less than 35 mmHg post-implant
Less than mild pulmonary regurgitation by angiography post-implant
Free of explant at 24 hours post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Procedural Adverse Event (AE)</measure>
    <time_frame>5 years</time_frame>
    <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Device-related Adverse Event</measure>
    <time_frame>5 years</time_frame>
    <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Freedom From Major Stent Fracture at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Major stent fracture is defined as a stent fracture requiring intervention to prevent permanent impairment of a body function or permanent damage to a body structure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Freedom From Catheter Re-intervention on TPV</measure>
    <time_frame>5 years</time_frame>
    <description>All Catheter Re-intervention on TPV at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Freedom From Surgical Replacement of the RVOT Conduit</measure>
    <time_frame>5 years</time_frame>
    <description>Freedom From Surgical Replacement of the RVOT Conduit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Freedom From Death (All-cause, Procedural and Device-related)</measure>
    <time_frame>5 years</time_frame>
    <description>Deaths (all-cause, procedural and device-related) at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment (NYHA Classification)</measure>
    <time_frame>6 Months</time_frame>
    <description>Improvement in Functional Assessment (NYHA Classification) at 6 months post implant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Congenital Heart Defects</condition>
  <condition>Dysfunctional Right Ventricular Outflow Tract Conduits</condition>
  <arm_group>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Pulmonary Valve replacement</intervention_name>
    <description>Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.</description>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <other_name>Melody Transcatheter Pulmonary Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 5 years of age

          -  Weight greater than or equal to 30 kilograms

          -  Existence of a full (circumferential) RVOT conduit that was equal to or greater than
             16 mm in diameter when originally implanted, or a stented bioprosthesis with a rigid
             circumferential sewing ring in the RVOT that has an internal diameter greater than or
             equal to 18 mm and less than or equal to 22 mm when originally implanted.

          -  Any of the following by transthoracic echocardiography:

          -  For patients in New York Heart Association (NYHA) Classification II, III, or IV:
             Moderate (3+) or severe (4+) pulmonary regurgitation AND/OR Mean RVOT gradient greater
             than or equal to 35 mmHg

          -  For patients in NYHA Classification I:Severe (4+) pulmonary regurgitation with RV
             dilatation or dysfunction AND/OR Mean RVOT gradient greater or equal to 40 mmHg

        Exclusion Criteria:

          -  Active endocarditis

          -  Major or progressive non-cardiac disease (liver failure, renal failure, cancer)that
             has a life expectancy of less than one year

          -  Patient or guardian unwilling or unable to provide written informed consent or comply
             with follow-up requirements

          -  Obstruction of the central veins (including the superior and inferior vena cava,
             bilateral iliac veins) such that the delivery system cannot be advanced to the heart
             via transvenous approach from either femoral vein or internal jugular vein

          -  Positive urine or serum pregnancy test 24 hours prior to procedure in female patients
             of child bearing potential

          -  Known intravenous drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of NY-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's and Regional Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enrolled</title>
          <description>All subjects enrolled (n=171)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Catheterized</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Further testing contraindicated implant</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All stubjects enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Cohort</title>
          <description>All subjects enrolled</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Freedom From TPV Dysfunction</title>
        <description>To assess whether long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. This study is designed to test the null hypothesis that the true freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is less than or equal to 36% (PControl). To reject the null hypothesis means that freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is greater than 36% (PControl). The null (H0) and alternative (HA) hypotheses are written as follows:H0: PMelody â‰¤ PControl and HA: PMelody &gt; PControl. TPV dysfunction is a composite outcome defined as the following:
Hemodynamic dysfunction of the TPV
Moderate or greater pulmonary regurgitation, and/or
Mean Right Ventricular Outflow Tract (RVOT) gradient greater than 40 mmHg
RVOT reoperation for conduit dysfunction or device-related reasons
Catheter re-intervention on the TPV</description>
        <time_frame>5 years</time_frame>
        <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hour Cohort</title>
            <description>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From TPV Dysfunction</title>
          <description>To assess whether long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. This study is designed to test the null hypothesis that the true freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is less than or equal to 36% (PControl). To reject the null hypothesis means that freedom from TPV dysfunction at 5 years after Melody implantation (PMelody) is greater than 36% (PControl). The null (H0) and alternative (HA) hypotheses are written as follows:H0: PMelody â‰¤ PControl and HA: PMelody &gt; PControl. TPV dysfunction is a composite outcome defined as the following:
Hemodynamic dysfunction of the TPV
Moderate or greater pulmonary regurgitation, and/or
Mean Right Ventricular Outflow Tract (RVOT) gradient greater than 40 mmHg
RVOT reoperation for conduit dysfunction or device-related reasons
Catheter re-intervention on the TPV</description>
          <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="65.5" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Z test</method>
            <param_type>Kaplan-Meier Rate</param_type>
            <param_value>74.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>67.1</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is a composite outcome defined as:
Melody TPV fixated within the desired location
Right Ventricle (RV) - Pulmonary Artery (PA) peak-to-peak gradient (measured in the catheterization lab) less than 35 mmHg post-implant
Less than mild pulmonary regurgitation by angiography post-implant
Free of explant at 24 hours post-implant</description>
        <time_frame>Within 24 Hours post implant</time_frame>
        <population>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</population>
        <group_list>
          <group group_id="O1">
            <title>Attempted Implant Cohort</title>
            <description>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is a composite outcome defined as:
Melody TPV fixated within the desired location
Right Ventricle (RV) - Pulmonary Artery (PA) peak-to-peak gradient (measured in the catheterization lab) less than 35 mmHg post-implant
Less than mild pulmonary regurgitation by angiography post-implant
Free of explant at 24 hours post-implant</description>
          <population>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Procedural Adverse Event (AE)</title>
        <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
        <time_frame>5 years</time_frame>
        <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheterized Cohort</title>
            <description>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Procedural Adverse Event (AE)</title>
          <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
          <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Device-related Adverse Event</title>
        <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
        <time_frame>5 years</time_frame>
        <population>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted Cohort</title>
            <description>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Device-related Adverse Event</title>
          <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
          <population>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Freedom From Major Stent Fracture at 5 Years</title>
        <description>Major stent fracture is defined as a stent fracture requiring intervention to prevent permanent impairment of a body function or permanent damage to a body structure.</description>
        <time_frame>5 years</time_frame>
        <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hour Cohort</title>
            <description>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Major Stent Fracture at 5 Years</title>
          <description>Major stent fracture is defined as a stent fracture requiring intervention to prevent permanent impairment of a body function or permanent damage to a body structure.</description>
          <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="77.5" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Freedom From Catheter Re-intervention on TPV</title>
        <description>All Catheter Re-intervention on TPV at 5 years</description>
        <time_frame>5 years</time_frame>
        <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hour Cohort</title>
            <description>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Catheter Re-intervention on TPV</title>
          <description>All Catheter Re-intervention on TPV at 5 years</description>
          <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="72.5" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Freedom From Surgical Replacement of the RVOT Conduit</title>
        <description>Freedom From Surgical Replacement of the RVOT Conduit</description>
        <time_frame>5 years</time_frame>
        <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hour Cohort</title>
            <description>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Surgical Replacement of the RVOT Conduit</title>
          <description>Freedom From Surgical Replacement of the RVOT Conduit</description>
          <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="85.8" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Freedom From Death (All-cause, Procedural and Device-related)</title>
        <description>Deaths (all-cause, procedural and device-related) at 5 years</description>
        <time_frame>5 years</time_frame>
        <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheterized Cohort</title>
            <description>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Death (All-cause, Procedural and Device-related)</title>
          <description>Deaths (all-cause, procedural and device-related) at 5 years</description>
          <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="91.1" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment (NYHA Classification)</title>
        <description>Improvement in Functional Assessment (NYHA Classification) at 6 months post implant.</description>
        <time_frame>6 Months</time_frame>
        <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours and had paired data from pre-implant to 6 months post-implant.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hour Cohort</title>
            <description>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment (NYHA Classification)</title>
          <description>Improvement in Functional Assessment (NYHA Classification) at 6 months post implant.</description>
          <population>The Implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours and had paired data from pre-implant to 6 months post-implant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time of consent through end of participation in the study.</time_frame>
      <desc>Any undesirable clinical occurrence or untoward deviation in health from the patientâ€™s baseline condition at the time of consent. Clinically significant worsening of a baseline condition requiring a new intervention, Deterioration of primary disease, Intercurrent illness, AEs related or possibly related to the implant that are greater in intensity and require different clinical intervention than normally required, and Abnormal findings on diagnostic tests not present at the onset of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Catheterized Cohort</title>
          <description>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valvular disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac conduction disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac disorders NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Heart failures NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pericardial disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary valvular disorders</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rate and rhythm disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tricuspid valvular disoders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmias and cardiac arrest</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Complications associated with device NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Device physical property and chemical issues</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cardiac infections</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sepsis, bacteraemia, viraemia and fungaemia NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac and vascular procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system haemorrhages and cerebrovascular accidents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Disturbances in consciousness NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nervous system disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure and impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax and pleural effusions NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombotic and embolic conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Respiratory tract disorders NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rashes, eruptions and exanthems NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysms and artery dissections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemorrhages NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Non-site specific embolism and thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vascular injuries NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolyses NEC</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device physical property and chemical issues</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorders NEC</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Patterson</name_or_title>
      <organization>Medtronic</organization>
      <phone>763.526.1544</phone>
      <email>susan.patterson@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

